Mateon Provides Update on its R&D Effort Against COVID-19
30 avr. 2020 06h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Published...
Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients
27 avr. 2020 08h00 HE
|
Mateon Therapeutics
AGOURA HILLS, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug...
IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma
17 avr. 2020 13h26 HE
|
RedHill Biopharma Ltd.
Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S.--Opaganib’s unique mechanism of...
7 Hills Pharma Announces FDA Clearance of Investigational New Drug Application for 7HP349, a First-in-Class Immune Stimulant
14 avr. 2020 08h00 HE
|
7 Hills Pharma
HOUSTON, April 14, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases,...
Q2Earth Signs Exclusive Option Agreement to License Promising Drug to Treat Bone Cancer in Children
22 janv. 2020 09h00 HE
|
Q2Earth, Inc
Palm Beach, FL, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Q2Earth, Inc. (OTCQB: QPWR) (the “Company” or “Q2”) announced today that it has signed an Exclusive Dealing Option Agreement to provide the Company...
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
10 janv. 2020 07h05 HE
|
LogicBio Therapeutics
– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...
Novan Further Expands its Proprietary Nitric Oxide Platform
18 oct. 2019 08h30 HE
|
Novan, Inc.
A new product candidate, SB207, to target anti-viral opportunitiesPre-IND meeting anticipated in December 2019Development of SB207 to be focused on indications with unmet patient need, such as...
Qrons Appoints Veteran U.S. Based Biotech Executive Dr. John N. Bonfiglio to Lead IND and Capital Markets Related Activities
27 juin 2019 09h00 HE
|
Qrons Inc.
New York, NY, June 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions for the...
Qrons Appoints Dr. Motti Ratmansky as Special Advisor for IND & Clinical Trial Preparations
08 mai 2019 09h00 HE
|
Qrons Inc.
New York, NY, May 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Qrons Inc. (OTC: QRON), an emerging biotechnology company developing advanced stem cell-synthetic hydrogel-based solutions to...
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
29 avr. 2019 08h00 HE
|
TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...